false EX-98 OSD Test Company #1 9876543210 9876543210 2024-01-01 2024-03-31 9876543210 spac04:DeSpacProjectionPreparer1Member 2024-01-01 2024-03-31 9876543210 srt:DecreaseDueToSalesOfMineralsInPlace 2024-01-01 2024-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

Exhibit 98

THIS DOCUMENT IS A TECHNICAL ILLUSTRATION OF HOW CERTAIN DISCLOSURES IN SEC FILINGS ARE TO BE TAGGED. IT DOES NOT INDICATE WHICH PARTICULAR DISCLOSURES MUST BE INCLUDED AND/OR TAGGED IN COMMISSION FILINGS, AND IT DOES NOT CONSTITUTE LEGAL GUIDANCE OF ANY SORT.

Projected Financial Information

Entity1 and Entity2 do not as a practice make public projections as to future revenues, earnings or other results. However, in connection with the Entity1 Board’s evaluation of the Business Combination, and as part of Entity1's due diligence process, Entity2's management delivered financial projections to Entity1, including projections for revenue, cost of goods sold, gross profit, operating expenses and EBITDA .

In developing the financial projections, numerous material assumptions were made, with respect to Entity2's business for the periods covered by the financial projections, including but not limited to number of products, ramp up to revenue, research and development and funding to operate and expand.

The projections for Entity2's business are based on the following assumptions:

Revenue Assumptions

Product 1: based on capture of 0% of $200 million prescription analgesics market in 2025, increasing to 5% of a $300 million prescription analgesics market by 2029

Product 2 licensing model generating revenue based on a 2% license fee and licensee's capture of 0% of $250 million product market in 2025.

Cost of Goods Sold

Cost of goods sold assumptions were applied to the Product 1 based on input from manufacturer, on an estimated per product basis in 2026, and reaching a 40% volume discount by 2028, plus packaging, kitting, labeling, dispensing costs equal to 20% of the product cost

Expenses

Research and development expense, product development, and testing and was estimated at 25% of revenue in 2025 reducing gradually to 8% of revenue in 2029

Marketing and sales expense includes staff compensation, marketing expenses, and selling expenses of 10% of revenue in 2025 reducing gradually to 2.9% of revenue in 2029

These assumptions have been carefully considered and are deemed reasonable based on industry trends and Entity2's strategic initiatives.